Isoptin

Verapamil Hydrochloride, the active ingredient in Isoptin, is a calcium channel blocker presented as an oral tablet for oral administration. It is indicated for the management of hypertension, angina pectoris, and selected supraventricular tachyarrhythmias such as atrial fibrillation and atrial flutter in adult patients.

GNH USA supplies Isoptin as a licensed, GDP‑compliant international pharmaceutical product, providing reliable sourcing to hospitals, pharmacies, and clinics across global markets. The company adheres to European Union quality standards and supports procurement teams with regulatory documentation, shipping logistics, and post‑supply services.

Isoptin (verapamil) acts on the cardiovascular system by modulating calcium influx, and is used for the following conditions: - Hypertension: lowers blood pressure through peripheral vasodilation. - Angina pectoris: reduces myocardial oxygen demand and relieves chest pain. - Supraventricular tachyarrhythmias: controls heart rate and helps restore normal rhythm in atrial fibrillation and atrial flutter.

Verapamil may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate headache. - Dizziness: sensation of light‑headedness. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Bradycardia: dangerously slow heart rate. - Heart block: impaired AV‑node conduction. - Severe hypotension: marked drop in blood pressure.

When prescribing Isoptin, clinicians should consider several precautionary measures. - Dose adjustment: required in hepatic impairment. - Renal function: monitor in severe renal failure. - Concomitant beta‑blockers: increased risk of bradycardia. - Pregnancy: use only if clearly needed after risk assessment. - Drug interactions: review all concomitant medications. - Store at ambient temperature: keep in original container, protect from moisture and light.

Verapamil interacts with several medicines; careful assessment is essential.

Major Interactions (Avoid): - Beta‑blockers: additive bradycardia and AV block. - CYP3A4 inhibitors (e.g., ketoconazole): increased verapamil levels. - Digoxin: heightened risk of digoxin toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduced verapamil efficacy. - Aspirin and NSAIDs: may blunt antihypertensive effect. - Statins metabolized by CYP3A4: increased statin exposure, risk of myopathy.